Lucid Diagnostics Management
Management criteria checks 4/4
Lucid Diagnostics' CEO is Lishan Aklog, appointed in Oct 2021, has a tenure of 3.25 years. total yearly compensation is $300.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.12% of the company’s shares, worth $996.82K. The average tenure of the management team and the board of directors is 3 years and 6.7 years respectively.
Key information
Lishan Aklog
Chief executive officer
US$300.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 3.3yrs |
| CEO ownership | 2.1% |
| Management average tenure | 3yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
May 09
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely
Dec 15Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio
Aug 11We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
Jul 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$52m |
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$300k | US$300k | -US$53m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$57m |
| Mar 31 2023 | n/a | n/a | -US$60m |
| Dec 31 2022 | US$456k | n/a | -US$56m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$37m |
| Dec 31 2021 | US$7m | n/a | -US$28m |
Compensation vs Market: Lishan's total compensation ($USD300.00K) is below average for companies of similar size in the US market ($USD645.26K).
Compensation vs Earnings: Lishan's compensation has been consistent with company performance over the past year.
CEO
Lishan Aklog (58 yo)
3.3yrs
Tenure
US$300,000
Compensation
Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 3.3yrs | US$300.00k | 2.12% $ 996.8k | |
| President & COO | 2.8yrs | US$162.50k | 0.96% $ 451.2k | |
| Chief Financial Officer | 6.7yrs | US$225.00k | 1.89% $ 890.5k | |
| General Counsel & Secretary | 2.7yrs | US$250.00k | 0.75% $ 354.1k | |
| Co-Founder & Strategic Advisor | no data | US$924.54k | no data | |
| Co-founder & Strategic Advisor | no data | no data | no data | |
| Co-Founder & Strategic Advisor | no data | no data | no data | |
| Co-Founder & Strategic Advisor | no data | no data | no data | |
| Chief Technology & Compliance Officer | no data | no data | no data | |
| Chief Scientific Officer | 3.3yrs | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Senior VP | less than a year | no data | no data |
3.0yrs
Average Tenure
58yo
Average Age
Experienced Management: LUCD's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 6.7yrs | US$300.00k | 2.12% $ 996.8k | |
| Independent Vice Chairman of the Board & Lead Independent Director | 3.5yrs | US$214.75k | 0.22% $ 102.9k | |
| Independent Director | 3.3yrs | US$262.25k | 0.19% $ 88.5k | |
| Independent Director | 3.8yrs | US$252.25k | 0.19% $ 88.5k | |
| Independent Director | less than a year | no data | 0.090% $ 42.4k | |
| Independent Director | 6.7yrs | US$227.75k | 0.34% $ 160.5k | |
| Member of Medical Advisory Board | 6.7yrs | no data | no data | |
| Chair of Medical Advisory Board | 6.7yrs | no data | no data | |
| Member of Medical Advisory Board | 6.7yrs | no data | no data | |
| Member of Medical Advisory Board | 6.7yrs | no data | no data | |
| Member of Medical Advisory Board | 6.7yrs | no data | no data | |
| Member of Medical Advisory Board | 4.5yrs | no data | no data |
6.7yrs
Average Tenure
69yo
Average Age
Experienced Board: LUCD's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 01:39 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lucid Diagnostics Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |